References
- Lexchin J, Bero LA, Djulbegovic B, Clark 0. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BE Med. j 326(7400), 1167–1170 (2003).
- Cho MK, Bern LA. The quality of drug studies published in symposium proceedings. Ann. Intern. Med 124(5), 485–489 (1996).
- Clifford TJ, Barrowman NJ, Moher D. Funding source, trial outcome and reporting quality: are they related? Results of a pilot study. BMC Health Serv Res. 2(1), 18 (2002).
- Kassirer J, Angell M. The journal's policy on cost-effectiveness analyses. N Engl. J. Med. 331(10), 669–670 (1994).
- Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann. Intern. Med. 123(1), 59–60 (1995).
- Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAIVIA 282(15), 1453–1457 (1999).
- Barbieri M, Drummond ME Conflict of interest in industry-sponsored economic evaluations: real or imagined? CUI7: Oncol Rep. 3(5), 410–413 (2001).
- Knox KS, Adams JR, Djulbegovic B, Stinson TJ, Tomor C, Bennet CL. Reporting and dissemination of industry versus nonprofit sponsored economic analyses of six novel drugs used in oncology. Ann. 0=1.11(12), 1591–1595 (2000).
- Drummond ME A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? PharmacoEconomics 14(1), 1–9 (1998).